SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Pivotal data sets up Tecentriq filing in small cell lung cancer

Tecentriq (atezolizumab) as a front-line therapy in combination with chemotherapy for ES-SCLC. ... Typically, 5% or less of ES-SCLC patients – in whom the tumour has spready beyond the lung and adjacent lymph nodes – are still alive after five years.

Latest news

AbbVie slumps on trial results for would-be blockbuster Rova-T

potential while moving swiftly ahead with additional trials in both second-line (TAHOE) and first-line SCLC (MERU). ... and remain committed to developing Rova-T for the treatment of patients with SCLC.".
Biotecnol taps into Cancer Research UK network for first trial

despite treatment, particularly mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), and renal cell carcinoma.
AbbVie's PARP inhibitor veliparib fails to deliver

Rova-T for small cell lung cancer (SCLC) and ABT-414 for the brain cancer glioblastoma.
Unhappy times continue at OncoMed with more disappointing results

progression-free survival (PFS) or overall survival (OS) when added to chemotherapy in patients with small-cell lung cancer (SCLC) in the PINNACLE trial.
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

Seattle Genetics also gets rights to the drug in other indications, including urothelial cancer (UC), small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), which are currently at

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Client Services Director - Med Comms: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Editorial Director – Medical Education (MedComms): Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director – Healthcare Advertising - London: Neg

Senior Account Manager: Competitive salary commensurate with experience

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....